BioCentury
ARTICLE | Company News

BDL, Sorrento deal

October 12, 2015 7:00 AM UTC

In August, Sorrento’s TNK Therapeutics Inc. subsidiary purchased BDL for $100 plus $6 million in TNK stock. TNK gains two clinical-stage CAR-modified T cell immunotherapy programs in solid tumors and ...